RXST vs SGP
RXST: RxSight is the only company commercializing light-adjustable intraocular lenses that let surgeons customize patient vision after cataract surgery, eliminating pre-operative guesswork. SGP: Spyglass Pharma is a clinical-stage biotech developing an innovative sustained-release drug delivery platform to improve patient outcomes in cataract surgery.
Side-by-side fundamentals
| Metric | RXST | SGP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.39 | $20.54 | |
| Market cap as of 2026-07-23 | $223M | $682M | |
| PEG as of 2026-07-23 | -0.07 | n/a | |
| Net margin as of 2026-07-23 | -36.6% | n/a | |
| Gross margin as of 2026-07-23 | +77.0% | n/a | |
| Operating margin as of 2026-07-23 | -43.4% | n/a | |
| ROE as of 2026-07-23 | -17.0% | -75.4% | RXST higher |
| ROA as of 2026-07-23 | -15.1% | -68.8% | RXST higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | SGP lower |
| Revenue growth (YoY) as of 2026-07-23 | -14.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +40.0% | n/a | |
| Beta as of 2026-07-23 | 1.17 | 0.97 | |
| 1-year return as of 2026-07-22 close | -28.6% | -23.2% | SGP higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.